Viral hepatitis.
Developments over the last four years in our understanding of viral hepatitis are analyzed. The molecular structure of hepatitis A has been established, and vaccines for prevention are under development. The recognition of the replicative and integrated stages of hepatitis B infection has allowed more rational approaches to therapy. Vaccines are of proven value. Delta virus infection has assumed an important role world wide as a cause of serious and fulminant liver disease in hepatitis B carriers. The agents for non-A, non-B virus hepatitis have eluded identification. These are important causes of chronic liver disease particularly in recipients of blood transfusion.
D002353:Carrier State; D002908:Chronic Disease; D006506:Hepatitis A; D006509:Hepatitis B / Q000175:diagnosis / Q000453:epidemiology / Q000517:prevention & control / Q000635:transmission; D017325:Hepatitis B Vaccines; D006526:Hepatitis C; D003699:Hepatitis D; D006525:Hepatitis, Viral, Human; D006801:Humans; D007370:Interferon Type I / Q000627:therapeutic use; D012008:Recurrence; D014761:Viral Hepatitis Vaccines / Q000008:administration & dosage
D017325:Hepatitis B Vaccines; D007370:Interferon Type I; D014761:Viral Hepatitis Vaccines